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Abstract
there are some agents that can be used for its treatment, and they are grouped according to different lines. 
However, their pharmacological effectiveness is only proved on a reduced number of patients. For this 
reason, new therapeutic strategies need to be developed. Certain molecules currently are on the initial 
stages of human clinical trials, and many of them are showing encouraging results. Furthermore, there is 
an increasingly accurate knowledge about the different molecular pathways related to NP. This advance is 
promoting the development of new molecules with potential therapeutic targets. Some of these agents are 
-
macological treatment in NP is becoming more important in clinical practice through alternatives such as 
radio frequency, stimulation, and nerve block therapy. The aim of this work is to review the state of art 
of NP treatment. For that purpose, the agents approved until today and their main action mechanisms 
should be considered, with a special emphasis on some of the latest molecules used on human clinical 
trials and those which are in development with animal models. Moreover, some of the main non-pharma-
cological strategies used to manage pain nowadays are also reviewed.
Keywords: neuropathic pain, new agents, pharmacological treatment, non-pharmacological treatment, 
clinical trial.
1. Introduction
Neuropathic Pain (NP) is caused by a disease or a 
direct injury of the central or peripheral nervous 
system, and it comprises a wide range of etiological 
determine the prevalence of NP, it is estimated that 
7-10% of the population suffer from it. Accordingly, 
-
mon population groups affected by NP (2). Nor-
mally, the most frequently affected areas are the 
hind neck, the lumbar region, and lower and higher 
extremities (3). Among the different pathologies 
that are commonly related to this kind of pain, it 
is important to highlight peripheral neuropathies, 
post-herpetic neuralgia, traumatic nerve injury, spi-
nal cord injury, multiple sclerosis, stroke, and va-
rious types of cancer (3).
NP is considered by many experts as one of the 
-
nage (2). The treatment complexity of this syndro-
me has led to the development of multiple clinical 
trials, meta-analyses, and clinical guidelines such 
as those of the International Association for the 
evidence and these guidelines, the pharmacologi-
cal treatment of NP usually follows different lines, 
each of them with its own pharmacological group 
the relief obtained is quite limited after applying all 
of the pharmacological lines.
Currently, there are some agents for NP treat-
achieving promising results (6, 7). On the other 
hand, several potential therapeutic targets have 
been proposed based on a better understanding of 
NP physiopathology and on the results achieved 
with animal models (8). Finally, it is important to 
bear in mind that NP treatment and management 
include non-pharmacological measures, and that 
there are some therapies, such as stimulation and 
nerve blocks, that are increasingly becoming rele-
vant (9).
This article aims at reviewing the state of art re-
garding NP pharmacological treatment by exami-
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ning the latest international clinical guidelines, the 
treatments with better results in later stage clinical 
trials, and the experimental development of agents 
in animal models. Furthermore, some of the poten-
tial therapeutic targets that have recently been pro-
posed are also reviewed.
treatment  
With regard to the NP pharmacological treatment, 
several treatment lines have demonstrated their 
-
tidepressants (TCAs), and selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs).
2.1. First-line agents
TCAs (e.g. amitriptyline) belong to this group. They 
inhibit serotonin and norepinephrine reuptake, 
which increases the top-down inhibitory control 
of pain (10). However, they also act on the sodium 
channel, beta-2 adrenergic receptors, and N-me-
thyl-d-aspartate (NMDA) receptors, thus produ-
cing side effects such as sedation, dizziness, dry 
-
re, SNRIs (e.g. duloxetine and venlafaxine) are also 
results in many cases, being nausea their most com-
mon side effect (11). Finally, anticonvulsants (e.g. 
pregabalin and gabapentin) have also demonstra-
They reduce the calcium entry in the dorsal horn of 
the spinal cord, decreasing the central sensitization 
(10). As they often cause drowsiness, dizziness, and 
edemas, it is recommended to start the treatment at 
2.2. Second-line agents
Tramadol can be mentioned among the second-line 
agents. It is a weak opioid which acts as a weak mu 
receptor agonist, and as an SNRI. It is recommen-
ded to use Tramadol with caution due to the de-
pendence and abuse risks, and also due to its side 
effects, including nausea, confusion, drowsiness 
Other second-line treatments, especially recom-
mended for peripheral NP, are topical agents like 
patches block the sodium channel and decrease ner-
capsaicin patches cause the desensitization of the 
transient receptor potential vanilloid 1, and they 
2.3. Third-line agents
Strong opioids (e.g. oxycodone and morphine) 
have recently been promoted to third-line agents, 
second-line treatment (12). This is primarily due 
to their potential side effects, risks and the need 
for them to be monitored in NP treatment. These 
opioids are more likely than tramadol to cause with-
drawal, dependence, and abuse. Moreover, opioids 
can induce nausea, constipation, drowsiness, res-
piratory depression; and, eventually, hyperalgesia, 
2.4. Fourth-line agents
Although some agents are probably effective in cer-
tain subgroups of patients, the current recommen-
dations for the use of all other drug treatments for 
NP are weak or inconclusive (1). Recommended 
fourth-line treatments include other anticonvul-
sants (e.g. oxcarbazepine, topiramate), other strong 
opioids (tapentadol), and botulinum toxin, among 
others (11, 12).
Despite the availability of a large number of 
therapies, drugs largely used to relieve NP usually 
(Table 1). Therefore, the validation of novel agents 
and the study of potential therapeutic targets is be-
coming increasingly necessary (13).
3. New molecules in clinical trials
In the last few years, some clinical trials with active 
principles, which were targeted to different mole-
cules to relieve NP, have been conducted in humans 
(6, 7). Some of the drugs currently under develo-
pment are focused on voltage-gated ion channels 
(Na+, K+), on the endocannabinoid system, on the 
renin-angiotensin-aldosterone system (RAAS) or 
on the nerve growth factor (NGF) receptor (Table 
2).
3.1.1. Nav1.7 sodium channels
Nav1.7 is the voltage-gated sodium channel that 
predominantly expresses in nociceptors in the dor-
sal root of the spinal cord. It contributes to the ini-
tiation and the upstroke phase of the peripheral 
nociceptor action potential, as well as to synaptic 
transmission and to neuropeptide release in the 
dorsal horn of the spinal cord (6). Raxatrigine (14), 
-
tive inhibitors of Nav1.7 in phase 2 trial (raxatrigi-
ne, funamide) and phase 3 trial (vixotrigine) to treat 
NP in trigeminal neuralgia in the case of raxatrigine 
and vixotrigine, and postherpetic neuralgia in the 
case of funamide.
3.1.2. Kv7 potassium channels
Kv7 is a voltage-gated non-inactivating potassium 
channel, and its down-regulation has been implica-
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ted in several hyperexcitability-related disorders. 
Flupirtine, a Kv7 channel activator, has recently 
showed analgesic effects on refractory NP treat-
-
3.2. Endocannabinoid system
The endocannabinoid system includes two recep-
tors (CB1 and CB2), their endogenously produced 
ligands (anandamide and 2-arachidonoylglycerol), 
and a wide metabolic machinery. Nabilone, a syn-
thetic cannabinoid approved for nausea and vomi-
ting associated with chemotherapy, has showed 
including NP (7, 11). Notably, APD371, a highly 
selective agonist of the CB2, has obtained positive 
results in a phase Ib clinical trial in NP and osteoar-
thritic treatment (7). However, the development of 
selective agonists of the cannabinoid receptors is 
complex because they are involved in diverse phy-
siological processes. Some CB2 ligands produce no 
major side effects at the central nervous system.
The union of angiotensin II (Ang II) to its receptors, 
AT1 and AT2, acts as a neuromodulator in the brain 
and in the spinal cord. Ang II participates in the cen-
tral and peripheral regulation of sensory nervous in-
formation, nociception, and taste and visual system. 
Furthermore, the expression of AT1 receptors and 
the conversion of Ang II to Ang III in central nervous 
system neurons are involved in a descending pain 
modulation (6, 13). EMA401 is a selective antagonist 
of AT2 receptors that has proved to be an effective 
option in NP treatment in patients with postherpetic 
neuralgia in phase II of clinical trials (17).
This growth factor is involved in the painful phy-
siological response to harmful stimuli, and it is in-
creased in a great variety of cases of acute and chro-
nic pain. For this reason, molecules that act as NGF 
antagonists have been developed (6,13). Tanezu-
mab, a humanized IgG2 that blocks the interaction 
with neuropathic component in chronic back low 
pain than naproxen and placebo in phase II clinical 
trials (6).
Nowadays, over one hundred molecules with a the-
rapeutic potential in NP treatment are being deve-
loped. Most of the studies have been conducted on 
animals. Although many results are positive, they 
are not directly applicable to humans (13, 18). Some 
molecules of special interest are sigma receptors, 
ephrins, and endoplasmic reticulum stress (ERS) 
receptors.
Sigma receptors are chaperon-like proteins that act 
in combination with NMDA channels and enable 
plays an essential role in neuronal sensitization and 
in chronic pain development. This is why its action 
mechanism (Figure 1) is being thoroughly studied 
(19-21). Moreover, it has been demonstrated that 
nerve injuries increase the number of sigma-1 re-
ceptors in the damaged neurons (8). Some studies 
conducted on NP-induced mice with paclitaxel 
show that both pharmacological blockade with sig-
ma-1 antagonists, as well as the genetic deactiva-
tion of it in knockout mice, inhibit the NP caused 
by paclitaxel (21).
4.2. Ephrins 
Ephrins are receptor tyrosine kinase ligands invol-
ved in neural development. They present receptors 
in the laminae I-III of the dorsal horn and in dor-
sal root ganglion (DRG) neurons (22). In addition, 
they regulate the NMDA-dependent synaptic ac-
tivity and they participate in spinal pain proces-
sing. Ephrins participate as well in upstream pain 
mechanisms through phosphatidylinositol 3-kinase 
-
citability of nociceptive neurons and their synaptic 
plasticity.
4.3 Endoplasmic reticulum stress receptors
In the presence of stress molecules, an incorrect 
protein folding occurs in the endoplasmic reticu-
lum (ER). As a defense mechanism, the unfolded 
protein response (UPR) mediated by chaperones is 
triggered. This ER response can also be activated by 
-
lin proteins (BiP) belong to the chaperone family. 
Studies conducted in murine models with orofacial 
suggesting that chronic activation of the UPR sys-
tem may induce neuronal vulnerability in response 
to NP stimuli.
They are molecules involved in neuronal meta-
bolism and development. It has been observed an 
increase of Wnt3 in the dorsal horn of rats whose 
signaling inhibitor, XAV939, attenuated NP sensiti-
vity (26). Blocking Ryk in mice suppresses neuronal 
hyperexcitability and neuroplasticity in the dorsal 
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horn. Other studies suggest that intervening on the-
se receptors may have a therapeutic potential in NP 
treatment (18, 27, 28).
4.5 D-amino acid oxidase 
It is a peroxisomal enzyme that catalyzes the oxi-
dative deamination of D-amino acids. Intrathecal 
administration of D-amino acids oxidase (DAAO) 
inhibitors in murine models revealed NP reduction 
(29) and formalin-induced tonic phase pain (30).
expression of receptors, ion channels and other me-
diators altered in NP could be a therapeutic way. 
Several studies suggest that there is an alteration in 
the expression of these mediators by methyltrans-
ferases, demethylases, histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). In this 
-
mokines and that of HDACs on the expression of 
cytokines in glial cells and macrophages have been 
demonstrated (31).
treatment
There is a great variety of non-pharmacological te-
chniques that may complement NP treatment by 
playing an important role in the psychological we-
ll-being of the patient, as well as in the evolutionary 
course of pain (9).
5.1. Non-invasive therapies
Several clinical trials in humans have studied the 
relationship between physical activity and pain 
sensitivity. Physical exercise is associated with a 
greater tolerance to pain in chronic low back pain, 
33). Physiotherapy and techniques such as mirror 
therapy and graded motor imagery also appear to 
-
chotherapy, especially cognitive-behavioral thera-
participation in their painful condition and to redu-
ce its consequences at affective, functional and so-
cial levels, although there is no evidence to prove its 
5.2. Invasive and minimally invasive therapies
The invasive techniques used in pain treatment seem 
to be a valid therapeutic alternative for those patients 
with NP for whom other treatments have not been 
effective (1). The importance of these techniques has 
grown in the last few years, and it is expected to keep 
growing. They include radio frequency (RF), neuros-
timulation, and nerve block therapy, among others. 
5.2.1. Radio frequency 
RF is a minimally invasive technique that produces 
-
late the channel expressions in DRG. It also contri-
butes to the neuromodulation of the nervous sys-
treat joint and muscle pain, and it has been proved 
to be effective in cases of radicular pain and neural-
gia (36).
5.2.2. Neurostimulation
Spinal cord stimulation (SCS) and transcutaneous 
electrical nerve stimulation (TENS) are two remar-
kable techniques used in neurostimulation. On the 
one hand, SCS acts at the back of the spinal cord and 
how this produces analgesia (9). SCS is effective in 
the treatment of syndromes like failed back surgery 
syndrome and complex regional pain syndrome, 
among others (37). On the other hand, TENS is a 
widely used non-invasive technique that activates 
-
cacy has not been proved by any research yet (38).
5.2.3. Nerve block therapy
Nerve block therapy is a widely used procedure 
for chronic pain conditions. It is useful for both NP 
diagnosis and treatment (39). Guirguis et al. (40) 
reported the case of a patient with postoperative 
residual abdominal pain, which was refractory to 
invasive techniques. To determine the origin of the 
pain, it was necessary to perform a nerve block in 
the area where the patient had the pain. Then, the 
-
med and, by inserting a catheter which continuous-
ly infused a local anesthetic, the analgesic effect was 
maintained. 
6. Conclusions
NP treatment is a complex task that can be approa-
ched by both pharmacological and non-pharmaco-
logical methods. There are several groups inside 
the pharmacological ones. First-line agents include 
TCA, SNRI and anticonvulsive agents such as pre-
gabalin and gabapentin. Second-line agents include 
weak opioids (tramadol) and topical lidocaine or 
capsaicin. Among third-line agents, strong opioids 
like morphine stand out. Finally, fourth-line agents 
are represented by the use of strong opioids, botu-
linum toxin, and other anticonvulsive agents. Al-
though there is a wide variety of agents available, 
-
tients. Therefore, more powerful molecules should 
be designed.
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Nowadays, some of the most important molecu-
les in clinical trials act on ion channels (Nav 1.7, Kv 
7), on the endocannabinoid system, on the RAAS or 
on NGF receptors. Moreover, some other molecules 
are showing interesting results in animal models. 
The most relevant ones are those which interact 
Wnt/Ryk triad, DAAO, and several epigenetic re-
gulators. To conclude, non-pharmacological pain 
treatment is becoming increasingly important. This 
kind of treatment can be applied by using non-in-
vasive therapies (physical activity, physiotherapy, 
graded motor imagery, psychotherapy), and inva-
sive or minimally invasive therapies (RF, neurosti-
mulation, and nerve block therapy).
-
terest in this article.
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Annex I: Tables
GROUP DRUG SIDE EFFECTS
FIRST-LINE AGENTS
TCAs Amitriptyline
Sedation, dizziness, dry mouth, 




Venlafaxine Nausea, vertigo, sedation, dry mouth.
Anticonvulsants
Pregabalin





sion, drowsiness, headache, sei-
zure, orthostatic hypotension.





Local erythema, itching, bur-
ning, local pain.
THIRD-LINE AGENTS Strong opioids
Morphine
Oxicodona
Nausea, constipation, dizziness, 
drowsiness, respiratory depres-
sion, hyperalgesia, and endocri-
ne disruptions. 
Risk of overuse, dependence 
and withdrawal (symptoms).
OTHERS
Neurotoxins Botulinum toxin Injection site pain.
Other opioids Tapentadol
Nausea, constipation, dizziness, 
drowsiness, respiratory depres-






Drowsiness, dizziness, visual 
blurring, headache, nausea.
TCA: tricyclic antidepressant
SNRI: selective serotonin and norepinephrine reuptake inhibitor
Table 1: Neuropathic pain pharmacological treatment.
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Diana terapéutica Molécula Indicación estudiada
Canales Nav7
Raxatrigina Fase 2 Neuralgia del trigémino
Vixotrigina Fase 3 Neuralgia del trigémino







Dolor neuropático, entre otros
APD-371 Fase 1b Dolor neuropático y osteoarticular
-
tensina aldosterona EMA-401 Fase 2 Neuralgia postherpética
Factor de crecimiento 
neural Tanezumab Fase 2
Lumbalgia crónica con componente neu-
ropático
Table 2: Molecules used in clinical trials for neuropathic pain treatment.
 Possible mechanism for the action of sigma-1 receptor in neuronal sensitization and its inactiva-
tion by antagonists.
Source: Lee JH. Role of Sigma Receptor and Neurosteroids in Pain Sensation. Hanyang Med Rev. 2011;31(2):123
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